• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 3. Distinctive size effects of Pt nanoparticles immobilized on Fe3O4@PPy used as an efficient recyclable catalyst for benzylic alcohol aerobic oxidation and hydrogenation reduction of nitroaromatics
  Yu Long,Bing Yuan,Jianrui Niu,Xin Tong,Jiantai Ma New J. Chem., 2015,39, 1179-1185
• 4. Etching of glass microchips with supercritical water?
  Pavel Karásek,Jakub Grym,Michal Roth,Josef Planeta,Franti?ek Foret Lab Chip, 2015,15, 311-318
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Stemarane diterpenoids

Recent Advances in Oryzalexin S (143437-61-0) Research: A Comprehensive Review

Oryzalexin S (CAS: 143437-61-0) is a diterpenoid phytoalexin primarily found in rice (Oryza sativa), known for its significant role in plant defense mechanisms against pathogens. Recent studies have expanded its potential applications in the chemical, biological, and pharmaceutical fields, particularly due to its antimicrobial, anti-inflammatory, and anticancer properties. This research briefing synthesizes the latest findings on Oryzalexin S, focusing on its molecular mechanisms, biosynthesis pathways, and therapeutic potentials.

Recent investigations into Oryzalexin S have highlighted its unique chemical structure, which contributes to its bioactivity. The compound belongs to the oryzalexin family, characterized by a labdane-related diterpenoid skeleton. Advanced spectroscopic techniques, including NMR and mass spectrometry, have been employed to elucidate its structure-activity relationships. These studies reveal that subtle modifications in its functional groups can significantly alter its biological efficacy, opening avenues for synthetic analogs with enhanced properties.

One of the most promising areas of research involves the biosynthesis of Oryzalexin S. Recent genomic and metabolomic studies have identified key enzymes, such as diterpene synthases and cytochrome P450s, involved in its production. Genetic engineering approaches are being explored to enhance yield in microbial hosts, such as Escherichia coli and Saccharomyces cerevisiae, for scalable production. These advancements could address current limitations in natural extraction methods, which are often inefficient and environmentally taxing.

In the pharmaceutical domain, Oryzalexin S has demonstrated potent antimicrobial activity against multidrug-resistant pathogens, including Staphylococcus aureus and Candida albicans. Mechanistic studies suggest it disrupts microbial cell membranes and inhibits essential enzymatic pathways. Additionally, its anti-inflammatory properties, mediated through the suppression of NF-κB and MAPK signaling pathways, position it as a candidate for treating chronic inflammatory diseases. Preclinical trials are underway to evaluate its efficacy and safety in vivo.

Another groundbreaking application is in cancer therapy. Oryzalexin S has shown selective cytotoxicity against various cancer cell lines, including breast, lung, and colon cancers, while sparing normal cells. Researchers attribute this to its ability to induce apoptosis via mitochondrial dysfunction and ROS generation. Combination therapies with conventional chemotherapeutic agents are being investigated to enhance treatment outcomes and reduce side effects.

Despite these advancements, challenges remain in the clinical translation of Oryzalexin S. Issues such as poor solubility, bioavailability, and potential toxicity at higher doses need to be addressed. Novel drug delivery systems, including nanoparticles and liposomes, are being tested to improve its pharmacokinetic profile. Furthermore, regulatory hurdles and the need for extensive clinical trials pose significant barriers to its commercialization.

In conclusion, Oryzalexin S (143437-61-0) represents a versatile compound with broad applications in medicine and agriculture. Ongoing research continues to uncover its multifaceted roles, from pathogen resistance in crops to innovative therapeutic agents. Collaborative efforts among chemists, biologists, and pharmacologists are essential to harness its full potential and overcome existing limitations. This briefing underscores the importance of sustained investment in phytoalexin research to meet global health and agricultural challenges.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)